India's Bajaj Healthcare rises as insomnia pill trial gets regulatory nod

Bajaj Healthcare

06/10/2025 05:45

** Shares of Bajaj Healthcare BAJH.NS rise about 3% to 498 rupees

** The pharmaceutical co's insomnia pill Suvorexant receives SEC (subject expert committees) panel under India's drug regulator CDSCO nod for phase three clinical trials

** Phase three trial representing the final and most crucial step before regulatory submission- BAJH

     ** Stock down nearly 13% YTD

 (Reporting by Komal Salecha)

 ((Komal@thomsonreuters.com;))